About this trial
Discarded perfusate samples will be collected from donors after circulatory death (DCD) or donors after brain death (DBD) organs during the machine perfusion period prior to transplantation by the study team. FMN will be measured as is standard of care for all machine perfusion liver transplant cases at Cleveland Clinic.
Participating centers will be provided with sample collection and shipping instructions to ensure sample preservation in accordance with IATA guidelines. Samples from outside sites will not be stored for future research and will be discarded once analysis is completed.
After the collection of the samples from machine perfusion, the transplant procedure will continue according to standard process.
Eligibility criteria
Qualifiers
Age >18 years
Any graft type (DBD or DCD)
Any underlying recipient disease (i.e., end stage, liver tumour)
Any other donor risk factors and static cold storage time prior to NMP accepted by the participating center for transplantation in context of OrganOx metra use
Disqualifiers
Patients receiving a liver graft that is not perfused with OrganOx metra
Pediatric recipients (<18years)
Patients listed for super urgent liver transplantation due to acute liver failure
Patients receiving combined organ transplant (heart+liver, lung+liver, liver+kidney, liver+intestine)
Trial design
Treatments tested in this trial
- Not listed